ARTICLE | Clinical News
Lynparza olaparib: Phase III data
May 23, 2016 7:00 AM UTC
Top-line data from the double-blind, Asian Phase III GOLD trial in 525 patients with HER2-negative advanced gastric cancer who progressed after first-line therapy showed that twice-daily 100 mg oral L...